Introduction In recent years, as one of the drugs for the treatment of acute ischemic stroke
(AIS), the clinical application of tenecteplase is still controversial. Therefore, we aimed to …

Drug development for ischemic stroke is challenging as evidenced by the paucity of
therapeutics that have advanced beyond a phase III trial. There are many reasons for this …

Angioedema without concomitant urticaria is a well-known complication of treatment with the
recombinant tissue-type plasminogen activator (r-tPA) alteplase and its genetically modified …

Background The benefits and risks of tenecteplase (TNK) versus alteplase (ALT) have
recently been assessed in acute ischemic stroke (AIS) patients undergoing mechanical …

The body weight–based thrombolytic medication strategy in clinical trials shows critical
defects in recanalization rate and post-thrombolysis hemorrhage. Methods for perceiving …

Abstract Introduction United States stroke systems are increasingly transitioning from
alteplase (TPA) to tenecteplase (TNK). Real-world data on the safety and effectiveness of …

Background and aims Tenecteplase (TNK) offers logistical advantages in stroke thrombolytic
therapy with its single bolus administration compared with alteplase. We aim to investigate …

Background and Purpose Tenecteplase is a thrombolytic agent with pharmacological
advantages over alteplase and has been shown to be noninferior to alteplase for acute …

Objective To systematically compare the benefits and risks of all thrombolytic agents
(tenecteplase, reteplase, and alteplase) at different doses for thrombolytic therapy in patients …

Purpose Orolingual angioedema (OA) secondary to administration of thrombolytic therapy is
a rare, but serious, known adverse effect. Despite the lack of robust evidence for their use …